Good day, everyone, and welcome to Pfizer's third quarter 2024earnings conference callToday's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, chief investor relations officer and senior vice president. Please go ahead, ma'am. Francesca DeMartin...
which was Bristol-Myers' top selling drug in 2003; Comments from Andrew Bodnar, Bristol-Myers' senior vice president for strategy, medical and external affairs, regarding the test results; View of author that it is rare for a pharmaceutical company to pit their drug against a competitor's drug...
Pfizer Inc. announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President.
Ian Read joins Pfizer as Chief Executive Officer. Prior to this, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units—Primary Care, Specialty Care,...
Senior Vice President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. Prior to joining the company, Doug was with the United States Department of Justice as an Assistant U.S. Attorney in the Southern District of New York. Doug was a recipient of the ...
Chief Strategy and Innovation Officer, Executive Vice President Chris Boshoff, MD, PhD Chief Scientific Officer and President, Research & Development Alexandre de Germay Chief International Commercial Officer, Executive Vice President Dave Denton
Uwe Schoenbeck,就职于Senior Vice President,现任Pfizer Worldwide R&D一职。作为行业享有盛名的大咖,Uwe Schoenbeck行事低调,对工作热情饱满,多次受邀作为嘉宾出席各类大会,并发表了精彩演讲。2017年03月21日,Uwe Schoenbeck受邀参加了由DELIVER在上海市浦东新区张杨路777号主办的《亚太药物研发领袖峰会2017》,并发表了精...
Pfizer Inflammation & Immunology senior vice-president and chief scientific officer Michael Vincent said: “At Pfizer’s Immunology and Inflammation Research Unit, our ultimate goal is to advance potential cures for autoimmune disease, and we see AnTolRx’s approach to re-educate the immune response...
“Currently, treatment options for RSV are extremely limited and focus primarily on supportive care,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Bacterial Vaccines and Hospital, at Pfizer. “The proposed acquisition of ReViral’s pipeline of therapeutic cand...
Before joining Pfizer in 2007, D'Amelio worked for Alcatel-Lucent as chief administrative officer and senior executive vice president of Integration.7 Albert Bourla Albert Bourla held 194,312 shares of Pfizer as of March 16, 2023.2Bourla is chairman andchief executive officer (CEO)of Pfizer. He...